<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949894</url>
  </required_header>
  <id_info>
    <org_study_id>156-402-00144</org_study_id>
    <nct_id>NCT03949894</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease</brief_title>
  <acronym>ESSENTIAL</acronym>
  <official_title>Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow
      the progression of cyst development and renal function insufficiency in adult Korean patients
      diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at
      initiation of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidences of TEAEs</measure>
    <time_frame>during the tolvaptan treatment period and up to 7 days after the date of last dosing</time_frame>
    <description>The incidences of TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidences of TEAEs meeting any of the followings will be summarized.</measure>
    <time_frame>during the tolvaptan treatment period and up to 7 days after the date of last dosing</time_frame>
    <description>Liver injury [ALT or AST elevation (&gt;3 x ULN) or Total Bilirubin elevation (&gt;2 x ULN), etc.], AEs leading to death, Serious AEs, AEs leading to treatment discontinuation, AEs whose causal relationship with the IMP cannot be ruled out, Severe AEs, Dehydration, Effects on Sodium, Creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total kidney volume (TKV) annual mean percent change rate [%/year]</measure>
    <time_frame>from baseline to End of Treatment (Visit 25, Month 24)</time_frame>
    <description>Baseline TKV refers to the value measured during the screening period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (off-treatment)</measure>
    <time_frame>from baseline to the Follow-up visit (Visit 26, 7 days after End of Treatment(Visit 25, Month 24))</time_frame>
    <description>(off-treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (on-treatment)</measure>
    <time_frame>from Completion of Tolvaptan Titration Period (Visit 6, Week 4) to End of Treatment (Visit 25, Month 24)</time_frame>
    <description>(on-treatment)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
  <arm_group>
    <arm_group_label>tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>30mg and 15mg of Tolvaptan Tablet</description>
    <arm_group_label>tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who voluntarily participate by giving written informed consent on this trial

          2. Male and female patients aged ≥ 19 to ≤ 50 years

          3. Subjects diagnosed with ADPKD based on the Unified Criteria for Ultrasonographic
             diagnosis of ADPKD (Pei-Ravine Criteria)

          4. Subjects with confirmed CKD stages 1-3 at the screening visit

          5. Subjects with confirmed rapidly progressive typical ADPKD 'Typical ADPKD'

               -  refers to bilateral and diffuse distribution, with mild, moderate or severe
                  replacement of kidney tissue by cysts, where all cysts contribute similarly to
                  TKV.

        'rapidly progressive ADPKD'

          -  Patients will be defined as 'rapidly progressive ADPKD' if they meet any of the
             following criteria:

               -  Mayo class 1C, 1D or 1E

                    -  Truncating PKD1 mutation confirmed by genetic testing before participating
                       this trial ③ PRO-PKD score &gt; 6 ④ Patients with ADPKD with a decline in
                       Estimated glomerular filtration rate(eGFR) ≥ 5 mL/min/1.73 m2 within 1 year
                       from the screening visit or with an average annual decline in eGFR ≥ 2.5
                       mL/min/1.73 m2 over a period of 5 years (excluding patients with an eGFR
                       decline due to factors other than ADPKD, such as uncontrolled type 2
                       diabetes, early diabetic glomerular disease or immune-mediated
                       glomerulonephritis)

        Exclusion Criteria:

          1. Patients with hyponatremia or hypernatremia

          2. Patients with anuria

          3. Patients with volume depletion

          4. Patients who are unable to sense or appropriately respond to thirst

          5. Patients with contraindications to MRI assessment [e.g., ferromagnetic metal
             prosthesis, aneurysm clips, severe claustrophobia, large tattoo on the abdomen or
             back, etc.]

          6. Patients with severe renal impairment [e.g., patients with currently active
             glomerulonephritis, kidney cancer, having a single kidney, history of renal surgery
             within the last 3 years, etc.]

          7. Patients with severe hepatic impairment [e.g., cirrhosis, viral hepatitis, unspecified
             liver function test abnormalities (ALT or Aspartate aminotransferase(AST)) &gt; 3 x ULN
             or Total Bilirubin &gt; 2 x ULN), etc.]

          8. Patients with eGFR decline due to factors other than ADPKD (e.g., uncontrolled type 2
             diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis,
             etc.)

          9. Patients with a history of hypersensitivity and/or specific reactions to benzazepine
             or benzazepine derivatives (such as Benazepril), or tolvaptan

         10. Patients with hereditary problems of galactose intolerance, the Lapp lactose
             deficiency or glucose-galactose malabsorption, etc.

         11. Patients who need chronic diuretic use

         12. Patients who are receiving any experimental (not marketed) or approved therapies that
             may affect the treatment of ADPKD within 6 months from the screening visit [e.g.,
             anti-sense RNA therapy, rapamycin, sirolimus, everolimus and somatostatin analogs
             (octreotide, sandostatin), vasopressin antagonist (mozavaptan, conivaptan),
             vasopressin agonist (desmopressin)]

         13. Patients who have received cyst decompression or sclerotherapy within 3 years from the
             screening visit

         14. Patients with a history of taking tolvaptan within 6 months from the screening visit

         15. Patients who received any investigational medicinal product in another trial within 30
             days from the screening visit

         16. Fertile women who are currently pregnant or breat feeding, or not willing to use or
             capable of using acceptable contraceptive methods (abstinence, oral, implanted or
             injected hormonal methods of contraception, intrauterine device or barrier methods of
             contraception, such as condom, contraceptive diaphragm and spermicidal agents) to
             avoid pregnancy until completion of the trial

         17. Patients who are, in the opinion of the investigator, unable to comply with the
             administration of the Investigational Medicinal Product(IMP) or the trial procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HYOWON JEONG</last_name>
    <phone>+82 2 3287 9284</phone>
    <email>jhw0159@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Hoon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeon Soon Jung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Sook Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Yeop Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Lim Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Wook Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Wan Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Kyung, Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Pyeongchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Gyun Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Young Na</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curie Ahn, Ph.D.,</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeong-Cheon Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye In Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Hwa Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Beik Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Hyun Yoo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Kyu Oh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Soo Kim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

